Products
Pumitamig Biosimilar Bispecific Antibody (VEGF-A × PD-L1) for Research
Cat No.: GMP-Bios-INN-1349
Anti-VEGFA therapeutic antibody (Pre-made Pumitamig biosimilar,Bispec Mixed Domains (Fv entry)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pumitamig (development codes BNT327/BMS986545) is a humanized bispecific antibody targeting VEGF-A (VEGFA) and PD-L1 (CD274). It is developed by BioNTech SE for Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1349-1mg | 1mg | |
| GMP-Bios-INN-1349-10mg | 10mg | |
| GMP-Bios-INN-1349-100mg | 100mg | |
| GMP-Bios-INN-1349-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Pumitamig biosimilar, Bispec Mixed Domains (Fv entry), Anti-VEGFA;PDL1/CD274 Antibody: Anti-VEGFA/Vascular endothelial growth factor A/long form/L-VEGF therapeutic antibody |
| INN Name | Pumitamig |
| Target | VEGFA;PDL1/CD274 |
| Format | Bispec Mixed Domains (Fv entry) |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | 1bj1:HL:KJ/7v5n:BA:FE |
| 99% SI Structure | None |
| 95-98% SI Structure | 6bft:AB:HL/1cz8:HL:YX |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
